Haemophilus influenzae type b. Incidence rate and preventive vaccination

The article summarizes the existing knowledge on the infection caused by Haemophilus influenzaetypeb (Hib-infection). It examines clinical immunology aspects of vaccination against Hib-infection. The authors cite data on the incidence of invasive Hib-infections in the Russia and other countries. Special attention is given to preventive vaccination against Hib-infection. The article describes properties of polysaccharide and conjugate vaccines against Hib-infection and examines different immunization schedules, therapeutic indications and contraindications, potential adverse reactions, and the vaccination procedure.

гемофильная инфекция типа b (Hib-инфекция), капсульные полисахариды, вакцинопрофилактика, календарь прививок, полирибозилрибитолфосфат (PRP), полисахаридные вакцины, конъюгированные вакцины, комбинированные вакцины, haemophilus influenzae type b (Hib-infection), capsular polysaccharides, preventive vaccination, immunization schedule, polyribosylribitolphosphate (PRP), polysaccharide vaccines, conjugate vaccines, combination vaccines

1. Haemophilus influenzae bacteria. NIBSC/SCIENCE PHOTO LIBRARY. Available from: http://www.sciencephoto.com/media/11458/view.

2. Bogdanovich TM, Stecjuk OU, Krechikova OI, Boronina LG, Katosova LK, Faustova ME. Strachunskij LS, ed. Isolation, identification and antimicrobial susceptibility testing of Haemophilus influenzae. Clinical Microbiology and Antimicrobial Chemotherapy 2000; 2(2): 93–109 (in Russian).

3. Pfieffer R. Die Aetiologie der Influenza. Z Hyg Infect. 1893; 13: 357–86.

4. Epidemiology and prevention of vaccine-preventable diseases: The Pink Book: Course Textbook. 12th ed. Second Printing (May 2012). Available from: https://goo.gl/e6EOQy.

5. Tognotti E. Scientific triumphalism and learning from facts: bacteriology and the «Spanish flu» challenge of 1918. Soc Hist Med. 2003; 16(1): 97–110.

6. Haemophilus influenzae type b (Hib) Vaccination Position Paper. WHO. Weekly epidemiological record 2013; 88 (39): 413–28.

7. Watt JP, Wolfson LJ, O’Brien KL, Henkle E, Deloria-Knoll M, McCall N, et al. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. Lancet 2009; 374(9693): 903–11.

8. Moxon ER, Kroll JS. The role of bacterial polysaccharide capsules as virulence factors. Curr Top Microbiol Immunol. 1990; 150: 65–85.

9. Crisel RM, Baker RS, Dorman DE. Capsular polymer of Haemophilus influenzae, type b. I: Structural characterization of the capsular polymer of strain Eagan. J Biol Chem. 1975; 250(13): 4926–30.

10. Chandran A, Watt JP, Santosham M. Haemophilus influenzae vaccines. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines, 6th ed. Philadelphia, PA, Saunders-Elsevier; 2013. P. 560–621.

11. Mu XQ, Egelman EH, Bullitt E. Structure and function of Hib pili from Haemophilus influenzae type b. J Bacteriol. 2002; 184(17): 4868–74.

12. Briere EC, Rubin L, Moro PL, Cohn A, Clark T, Messonnier N. Prevention and control of haemophilus influenzae type b disease: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2014; 63 (RR-01): 1–14.

13. Fothergill LD, Wright J. Influenzal meningitis: the relation of age incidence to the bactericidal power of blood against the causal organism. J Immunol. 1933; 24: 273–84.

14. Käyhty H, Peltola H, Karanko V, Mäkelä PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis. 1983; 147(6): 1100.

15. Notifiable diseases and mortality tables. Morbidity and Mortality Weekly Report (MMWR) 2015; 64(01): ND-1-ND-19. Available from: https://goo.gl/YTRlV9.

16. MR 3.3.1.0001–10 Epidemiology and vaccine prevention of infections caused Haemophilus influenzae type b. Methodical recommendations. 2010 (in Russian).

17. Chandrasekar PH, Cavaliere R, Rust RS, S Swaminathan. Haemophilus meningitis. Available from: https://goo.gl/NGBAEI.

18. Ozeretskovsky NA, Nemirovskaya TI. Vaccination against Haemophilus influenzae type b in the Russian Federation and Abroad. Epidemiology and Vaccinal Prevention 2016; 15(1): 61–6 (in Russian).

19. Uchaikin VF, Shamsheva OV, Mikhailova ÅÌ, Shvedova NM. National calendar of preventive vaccination: problems, solutions and results in Saratov region. Saratov Journal of Medical Scientific Research 2013; 9(2): 192–6 (in Russian).

20. O’Neill JM, St Geme JW 3rd, Cutter D, Adderson EE, Anyanwu J, Jacobs RF, Schutze GE. Invasive disease due to nontypeable Haemophilus influenzae among children in Arkansas. J Clin Microbiol. 2003; 41(7): 3064–9.

21. Faden H, Duffy L, Williams A, Krystofik DA, Wolf J. Epidemiology of nasopharyngeal colonization with nontypeable Haemophilus influenzae in the first 2 years of life. J Infect Dis. 1995; 172(1): 132–5.

22. Cochi SL, Fleming DW, Hightower AW, Limpakarnjanarat K, Facklam RR, Smith JD, et al. Primary invasive Haemophilus influenzae type b disease: a population-based assessment of risk factors. J Pediatr. 1986; 108(6): 887–96.

23. Saha SK, Baqui AH, Darmstadt GL, Ruhulamin M, Hanif M, El Arifeen S, et al. Invasive Haemophilus influenzae type b diseases in Bangladesh, with increased resistance to antibiotics. J Pediatr. 2005; 146(2): 227–33.

24. Adegbola RA, Mulholland EK, Secka O, Jaffar S, Greenwood BM. Vaccination with a Haemophilus influenzae type b conjugate vaccine reduces oropharyngeal carriage of H. influenzae type b among Gambian children. J Infect Dis. 1998; 177(6): 1758–61.

25. Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev. 2000; 13(2): 302–17.

26. Kelly DF, Moxon ER, Pollard AJ. Haemophilus influenzae type b conjugate vaccines. Immunology 2004; 113(2): 163–74.

27. Käyhty H, Karanko V, Peltola H, Mäkelä PH. Serum antibodies after vaccination with Haemophilus influenzae type b capsular polysaccharide and responses to reimmunization: no evidence of immunologic tolerance or memory. Pediatrics 1984; 74(5): 857–65.

28. Peltola H, Käyhty H, Sivonen A, Mäkelä H. Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland. Pediatrics 1977; 60(5): 730–7.

29. Centers for Disease Control (CDC). Polysaccharide vaccine for prevention of Haemophilus influenzae type b disease. MMWR Morb Mortal Wkly Rep. 1985; 34(15): 201–5.

30. Dajani AS, Asmar BI, Thirumoorthi MC. Systemic Haemophilus influenzae disease: an overview. J. Pediatr. 1979; 94(3): 355–64. 31. Avery OT, Goebel WF. Chemo-immunological studies on conjugated carbohydrate-proteins : V. The immunological specifity of an antigen prepared by combining the capsular polysaccharide of type III Pneumococcus with foreign protein. J Exp Med. 1931; 54(3): 437–47.

31. Abramtseva MV, Tarasov AP, Nemirovskaya TI. Meningococcal disease. Meningococcal conjugate polysaccharide vaccines and new generation vaccines. Report 3. BIOpreparations. Prevention, Diagnosis, Treatment 2016; 16(1): 3–13 (in Russian).

32. Granoff DM, Rathore MH, Holmes SJ, Granoff PD, Lucas AH. Effect of immunity to the carrier protein on antibody responses to Haemophilus influenzae type b conjugate vaccines. Vaccine 1993; 11(Suppl 1): S46–S51.

33. Barington T, Gyhrs A, Kristensen K. Opposite effects of actively and passively acquired immunity to the carrier on responses of human infants to a Haemophilus influenzae type b conjugate vaccine. Infect Immun. 1994; 62(1): 9–14.

34. Mäkelä PH, Käyhty H, Leino T, Auranen K, Peltola H, Ekström N, Eskola J. Long-term persistence of immunity after immunisation with Haemophilus influenzae type b conjugate vaccine. Vaccine 2003; 22(2): 287–92.

35. Haemophilus influenzae type b (Hib): the green book. Chapter 16. Immunization against infections desease. 2013. Available from: https://goo.gl/vYT2f3.

36. Canadian immunization guide: Part 4 – Active vaccines. Haemophilus influenzae type b vaccine. 2014. Available from: https://goo.gl/ qgro1Z.

37. Haemophilus influenzae infections. Red Book. 29 ed.; Am Acad Pediatr. 2012. P. 345–52. Available from: https://goo.gl/sAmyoC.

38. Adams DA, Jajosky RA, Ajani U, Kriseman J, Sharp P, Onwen DH, et al. Summary of notifiable diseases – United States, 2012. MMWR Morb Mortal Wkly Rep. 2014; 61(53): 1–121.

39. Harris JB, Gacic-Dobo M, Eggers R, Brown DW, Sodha SV. Global routine vaccination coverage, 2013. MMWR Morb Mortal Wkly Rep. 2014; 63(46): 1055–8.

40. Groups with special vaccination requirements. The Australian immunization Handbook 10th, 2015. Available from: http://www.immunise.health.gov.au/7A5C97D9-EFF7-46D7-A8B8-AB0E73A4852E/ FinalDownload/DownloadId-E531F400104334DF0A8EAE21ECC5 39EA/7A5C97D9-EFF7-46D7-A8B8-AB0E73A4852E/internet/immunise/publishing.nsf/content/7B28E87511E08905CA257D4D00 1DB1F8/$File/Aus-Imm-Handbook.pdf.

41. Washburn LK, O’Shea TM, Gillis DC, Block SM, Abramson JS. Response to Haemophilus influenzae type b conjugate vaccine in chronically ill premature infants. J Pediatr. 1993; 123(5): 791–4.

42. Heath PT, Booy R, McVernon J, Bowen-Morris J, Griffiths H, Slack MP, et al. Hib vaccination in infants born prematurely. Arch Dis Child. 2003; 88(3): 206–10.

43. Kristensen K, Gyhrs A, Lausen B, Barington T, Heilmann C. Antibody response to Haemophilus influenzae type b capsular polysaccharide conjugated to tetanus toxoid in preterm infants. Pediatr Infect Dis J. 1996; 15(6): 525–9.

44. National Calendar of Prophylactic Immunization. Available from: https://goo.gl/CtAqe5 (in Russian).

45. WHO information sheet observed rate of vaccine Haemophilus influenzae type b (Hib) vaccine. April 2012. Available from: https:// goo.gl/ezGiwx.

46. Bohlke K, Davis RL, Marcy SM, Braun MM, DeStefano F, Black SB, et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics 2003; 112(4): 815–20.

47. Moro PL, Jankosky C, Menschik D, Lewis P, Duffy J, Stewart B, Shimabukuro TT. Adverse events follow Haemophilus influenzae type b vaccines in the Vaccine Adverse Event Reporting System, 1990–2013. J Pediatr. 2015; 166(4) 992–7.

48. MU 3.3.1.1095–02. Medical contraindications to prophylactic immunization using vaccines of the national immunization schedule. Methodology guidelines. 2002 (in Russian).